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Antibiotics are one of the most important medicines of the 21st 
century [1]. Due to the emergence and spread of multidrug resistant 
(MDR) bacteria, the therapy of infectious diseases may be jeopardized, 
leading to sequelae, decreased quality of life and excess mortality [2]. 
The spread of MDR pathogens is a major public health issue, which 
requires global action of an intersectoral nature, involving prudent use 
and prescribing, development of novel drug candidates, clinical trials 
and government action and financial support [3]. From the standpoint 
of antimicrobial drug resistance, the so-called “ESKAPE” pathogens 
(E: Enterococcus faecium, S: Staphylococcus aureus or recently 
Stenotrophomonas maltophilia, K: Klebsiella pneumoniae or recently 
C: Clostridioides difficile, A: Acinetobacter baumannii, P: Pseudomonas 
aeruginosa, E: Enterobacter spp., or recently Enterobacteriaceae) are 
the most concerning [4-6]. In the clinical practice, in addition to the 
susceptibility of the bacteria, other factors also influence the choice of 
antimicrobial drugs, such as the age (infants, children), pregnancy/
lactation or the general state of the patient [7]. Several drugs may be 
useful is almost all conditions (e.g., beta-lactams or macrolides if allergy 
is not detected), while other may not be administered due to their dose-
limiting side effects or teratogenicity (fluoroquinolones, tetracyclines), 
further limiting therapeutic options [8]. Another important factor to 
consider is the administration route of the antimicrobials: this may 
occur orally (per os) or parenterally (i.v. or i.m.). The possible routes 
for the administration of the antimicrobials principally depends on the 
bioavailability of these drugs in vivo.
In pharmacology, bioavailability represents the fraction of an 
administered dose of unchanged drug reaching the systemic circulation 
[9]. As a general rule, intravenous administration represents 100% 
bioavailability, while if a medication is administered via other routes 
(e.g., per os), its bioavailability is generally lower, due to incomplete 
absorption, first-pass metabolism (FPM) in the liver and additional 
factors; therefore, bioavailability may vary from patient to patient [9]. 
Drug–drug interactions (inducing or inhibiting various cytochrome 
P450 enzymes; predominantly the CYP3A4, CYP2C9 and CYP2D6 
isoenzymes), should also be considered during the choice of therapy, 
as they affect therapeutic response by modulating the degradation 
of medicinal drugs [10]. Bioavailability should always be included 
during dose calculations in the clinical practice. In addition, the 
tissue penetration of drug molecule should also be adequate to attain 
therapeutic concentrations in including peripheral parts of the body 
(i.e. in infected sites that are hard-to-reach and that have specific 
physico-chemical characteristics, like the central nervous system [CNS], 
bone tissue, abscesses) [11]. During drug design and development, 
Lipinsky’s Rule of Five (RO5) is generally used as an indicator of drug-
likeness. Based on these rules (1. ≤ 5 hydrogen bond donors, 2. ≤ 10 
hydrogen bond acceptors, 3. molecular mass < 500 Da, 4. octanol-water 
partition coefficient (clogP) < 5), it can be assumed that the most orally 
administered drugs are relatively small and moderately lipophilic 
molecules [12]. From the standpoint of pharmaceutical technology and 
formulations, the compounds should also be Class I molecules in the 
Biopharmaceutical Classification System (BCS) [13]. 
There have been several clinical studies and meta-analyses on 
comparing the efficacy of intravenous and oral antimicrobial therapy 
in various types of infections. None of these studies found oral therapy 
inferior to intravenous administration, therefore, if possible, this 
route should be primarily used [14-16]. There are several advantages 
to oral antibiotic therapy: it is cheaper (no need for needles, diluents, 
IV pumps, equipment) there is no need for an intravenous access or 
a central catheter (e.g., CVC), there are no associated complications 
(e.g., phlebitis, thrombosis, bloodstream infections), there is less 
concern regarding changes in the fluid balance of the patient (e.g., 
sulfamethoxazole/trimethoprim needs to be administered in a large 
volume i.v.) and it is more comfortable for the patients. On the other 
hand, for oral therapy, the patient needs to be conscious and has to 
have an intact gastrointestinal tract (not manageable in patients with 
swallowing difficulties, vomiting and absorption disorders), the onset 
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of clinical effects may take up to 30 minutes to 6 hours and some of 
the administered dose is lost to FPM in the liver [9]. In contrast, the 
dose of antimicrobial administered intravenously (through a drip or 
a bolus injection) ensures a rapid distribution and clinical response in 
the patient, and the bioavailability is 100% as the entire dose reaches 
the bloodstream (no FPE). Intravenous administration is also useful 
in cases where the patient is not able to take oral drugs, or an urgent 
effect is needed. In addition, for critically ill patients and in several 
indications (e.g., osteomyelitis, septic arthritis, sepsis/bacteremia, 
endocarditis, CNS/ocular infections), intravenous administration is 
still the preferred route of drug entry. There are several cases where 
the required therapeutic doses can only be reached through i.v. dosing; 
finally, some bacteria (especially in the therapy of MDR infections) can 
only be treated with antibiotics that are available in i.v. formulation 
only (e.g., ceftaroline-fosamil, daptomycin) or the therapeutic choices 
are limited to these drugs based on the antibiogram [17,18].
According to the data from the United States, more than 80% of 
drugs in current clinical use are orally administered (although this 
report was not limited to antibiotics) [19]. As previously mentioned, 
intravenous (IV) administration should only be utilized, if it is 
justified by the medical condition of the patient or the resistance 
trends associated with the pathogen. By definition, antibiotics with > 
90% bioavailability (trimethoprim-sulfamethoxazole, metronidazole, 
doxycycline, minocycline, clindamycin, metronidazole, linezolid, 
tedizolid, rifampin, clindamycin, most of the fluoroquinolones and the 
antifungal drugs fluconazole and voriconazole) are interchangeable/
equivalent in intravenous and oral antibiotic therapy and they are 
candidates for sequential therapy (IV-to-PO switches) [4]. The 
relevance of sequential antibiotic therapy is highlighted and encouraged 
in the era of prudent antibiotic use and antimicrobial stewardship 
[20]. Exceptions include ciprofloxacin (~70% bioavailability) and 
azithromycin (~40% bioavailability), as they still manage to achieve the 
therapeutic levels, when taken orally. Additionally, most of the beta-
lactam antibiotics are administered parenterally (iv. or im. injections 
and infusions), where instead of bioavailability, the main limiting 
issues are physico-chemical characteristics (e.g., degradation due to 
acid sensitivity) [21]. Clinicians should be aware of the advantages/
disadvantages and relevance of intravenous and oral antibiotics, and 
use them appropriately, based on the clinical situation, which needs 
to be evaluated on a case-by-case approach [22,23]. This topic should 
be further highlighted in university curricula and during continuous 
professional development (CPD) [22]. Clinical pharmacists have a 
pivotal role in advising clinicians towards the appropriate choice of 
antibiotics and formulations [24,25]. 
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